Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax plus fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC)

被引：0
|
作者：
Lindeman, Geoffrey J.
Fernando, Tharu M.
Bowen, Rebecca
Chang, Ching-Wei
Desai, Rupal
Gupta, Kushagra
Flechais, Aulde
Wilson, Timothy R.
Bardia, Aditya
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P5-13-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-13-06
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) plus fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).
    Lindeman, Geoffrey J.
    Bowen, Rebecca
    Jerzak, Katarzyna Joanna
    Song, Xinni
    Decker, Thomas
    Boyle, Frances M.
    McCune, Steven L.
    Armstrong, Anne
    Shannon, Catherine M.
    Bertelli, Gianfilippo
    Fernando, Tharu M.
    Desai, Rupal
    Gupta, Kushagra
    Hsu, Jerry Y.
    Flechais, Aulde
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer
    Darrigues, L.
    Pierga, J-Y
    Bernard, A.
    Bieche, I.
    Silveira, A.
    Michel, M.
    Sablin, M-P
    Cottu, P.
    Dubot, C.
    Geiss, R.
    Ricci, F.
    Proudhon, C.
    Bidard, F-C
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [4] FULVESTRANT COMBINED WITH CAPECITABINE MAY BE EFFECTIVE AND WELL TOLERATED FOR PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER
    Nakai, Maki
    BREAST, 2015, 24 : S50 - S51
  • [5] A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients
    Chan, Nancy
    Moore, Dirk
    Tandra, Pavankumar
    Rana, Jatin
    Omene, Coral
    George, Mridula
    Krishnamurthy, Jairam
    Desai, Shruti
    Patel, Nayana
    Wang, Yue
    Bicomong, Marc
    Tan, Xiao-Wei
    Hirshfield, Kim
    Ganesan, Shridar
    Toppmeyer, Deborah
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Hugo Herrscher
    Michel Velten
    Julie Leblanc
    Michal Kalish-Weindling
    Cathie Fischbach
    Delphine Exinger
    Xavier Pivot
    Thierry Petit
    Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
  • [7] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Herrscher, Hugo
    Velten, Michel
    Leblanc, Julie
    Kalish-Weindling, Michal
    Fischbach, Cathie
    Exinger, Delphine
    Pivot, Xavier
    Petit, Thierry
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376
  • [8] Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
    Jhaveri, K.
    Eli, L. D.
    Wildiers, H.
    Hurvitz, S. A.
    Guerrero-Zotano, A.
    Unni, N.
    Brufsky, A.
    Park, H.
    Waisman, J.
    Yang, E. S.
    Spanggaard, I.
    Reid, S.
    Burkard, M. E.
    Vinayak, S.
    Prat, A.
    Arnedos, M.
    Bidard, F. -C.
    Loi, S.
    Crown, J.
    Bhave, M.
    Piha-Paul, S. A.
    Suga, J. M.
    Chia, S.
    Saura, C.
    Garcia-Saenz, J. a.
    Gambardella, V.
    de Miguel, M. J.
    Gal-Yam, E. N.
    Raphael, A.
    Stemmer, S. M.
    Ma, C.
    Hanker, A. B.
    Ye, D.
    Goldman, J. W.
    Bose, R.
    Peterson, L.
    Bell, J. S. K.
    Frazier, A.
    Diprimeo, D.
    Wong, A.
    Arteaga, C. L.
    Solit, D. B.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 885 - 898
  • [9] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN
    Taheri, S.
    Majd, Karimi Z.
    Rezaei, S.
    Yousefi, N.
    Peiravian, F.
    VALUE IN HEALTH, 2019, 22 : S472 - S472
  • [10] Neratinib plus fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial
    Hyman, D.
    Piha-Paul, S.
    Saura, C.
    Arteaga, C.
    Mayer, I.
    Shapiro, G.
    Loi, S.
    Lalani, A.
    Xu, F.
    Cutler, R.
    Butturini, A.
    Bryce, R.
    Meric-Bernstam, F.
    Baselga, J.
    Solit, D.
    CANCER RESEARCH, 2017, 77
12345